NeoGenomics Launches PanTracer Pro for Solid Tumor Testing
The integrated testing approach combines genomic profiling with immunohistochemistry to support faster treatment decisions for advanced-stage cancer patients.
The integrated testing approach combines genomic profiling with immunohistochemistry to support faster treatment decisions for advanced-stage cancer patients.
The FDA has granted Breakthrough Device Designations to two 15-minute rapid tests for detecting Candida auris and carbapenem-resistant Acinetobacter baumannii, both identified by WHO as critical priority pathogens.
A longitudinal study finds blood-based biomarkers more sensitive than PET scans in detecting obesity's impact on Alzheimer's pathology.
Hims & Hers Health is now offering GRAIL’s Galleri multi-cancer blood test through its digital health platform, expanding access to screening for more than 50 cancer types, including those lacking established protocols.
Visby Medical and Watchmaker Genomics have partnered to develop at-home PCR respiratory tests designed to overcome molecular inhibitors found in unprocessed clinical samples, according to a joint announcement.
The company will process clinical samples for Path Fertility’s NOA Guide, an epigenetic test designed to inform surgical decision-making for men with non-obstructive azoospermia.
The test is being developed to differentiate between adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis at the point of care.
The test measures two sugar alcohols to detect SORD-related neuropathy, which standard genetic tests sometimes miss.
A large-scale international trial is evaluating a finger prick blood test for Alzheimer’s, analyzing three protein biomarkers as a potential alternative to PET scans and lumbar punctures.
Babson Diagnostics’ BetterWay GLP-1 blood testing panel is now available at more than 25 Austin and Temple, Texas, retail locations, including Sam’s Club and Peoples Rx pharmacies. The panel features 29 tests to support GLP-1 therapy.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The eight-minute test also shortened hospital stays by nearly two days at Froedtert Hospital, reinforcing previous multi-site evidence.